#######################
# Document Properties #
#######################
SET DOCUMENT Copyright   = "Copyright Â© 2018 Fraunhofer Institute SCAI, All rights reserved."
SET DOCUMENT Licenses    = "Private Ownership to Fraunhofer Institute SCAI"
SET DOCUMENT ContactInfo = "charles.hoyt@scai.fraunhofer.de"

SET DOCUMENT Name        = "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies"
SET DOCUMENT Version     = "1.0.0"
SET DOCUMENT Authors     = "Sandra Spalek"
SET DOCUMENT Description = ""

##############
# Namespaces #
##############

# Namespaces hosted on https://github.com/pharmacome/terminology
# --------------------------------------------------------------
DEFINE NAMESPACE CHEBI          AS URL "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/chebi-names.belns"
DEFINE NAMESPACE DRUGBANK       AS URL "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/drugbank-names.belns"
DEFINE NAMESPACE ECCODE         AS URL "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/ec-code.belns"
# DEFINE NAMESPACE FB           AS URL "https://raw.githubusercontent.com/pharmacome/terminology/80171ae62cf43aa1fc8a6c326b94537ab342458c/external/fb-names.belns"
DEFINE NAMESPACE HBP            AS URL "https://raw.githubusercontent.com/pharmacome/terminology/cf4d8bb88754f036b943b4d94ad96e103dcb7149/export/hbp-names.belns"
DEFINE NAMESPACE HGNC           AS URL "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/hgnc-names.belns"
DEFINE NAMESPACE HGNCGENEFAMILY AS URL "https://raw.githubusercontent.com/pharmacome/terminology/3074b85b858455d8eeb76cfcdef685ced19bbe11/external/hgnc.genefamily-names.belns"
DEFINE NAMESPACE GO             AS URL "https://raw.githubusercontent.com/pharmacome/terminology/a5b84013a08880975ca84f40999e4404b14a97e2/external/go-names.belns"
DEFINE NAMESPACE INTERPRO       AS URL "https://raw.githubusercontent.com/pharmacome/terminology/f2f993e599694ab5ce989cc39d789a499f75db99/external/interpro-names.belns"
DEFINE NAMESPACE MESH           AS URL "https://raw.githubusercontent.com/pharmacome/terminology/01c9daa61012b37dd0a1bc962521ba51a15b38f1/external/mesh-names.belns"
DEFINE NAMESPACE MGI            AS URL "https://raw.githubusercontent.com/pharmacome/terminology/f2f993e599694ab5ce989cc39d789a499f75db99/external/mgi-names.belns"
DEFINE NAMESPACE MIRBASE        AS URL "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/mirbase-names.belns"
DEFINE NAMESPACE NCBIGENE       AS URL "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/entrez.belns"
DEFINE NAMESPACE PFAM           AS URL "https://raw.githubusercontent.com/pharmacome/terminology/8ccfed235e418e4c8aa576f9a5ef0f838e794c7f/external/pfam-names.belns"
DEFINE NAMESPACE RGD            AS URL "https://raw.githubusercontent.com/pharmacome/terminology/f2f993e599694ab5ce989cc39d789a499f75db99/external/rgd-names.belns"

# Namespaces hosted on https://github.com/sorgerlab/famplex
# ---------------------------------------------------------
DEFINE NAMESPACE FPLX           AS URL "https://raw.githubusercontent.com/sorgerlab/famplex/e8ae9926ff95266032cb74f77973c84939bffbeb/export/famplex.belns"

# Namespaces hosted on https://arty.scai.fraunhofer.de/artifactory/bel/namespace
# ------------------------------------------------------------------------------
DEFINE NAMESPACE CTO            AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/clinical-trial-ontology/clinical-trial-ontology-1.0.0.belns"
DEFINE NAMESPACE DO             AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/disease-ontology/disease-ontology-20170725.belns"
DEFINE NAMESPACE HP             AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/hp/hp-20171108.belns"
DEFINE NAMESPACE SCOMP          AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/selventa-named-complexes/selventa-named-complexes-20170725.belns"
DEFINE NAMESPACE SFAM           AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/selventa-protein-families/selventa-protein-families-20170725.belns"

# Namespaces defined with regular expressions
# -------------------------------------------
DEFINE NAMESPACE DBSNP          AS PATTERN "rs[0-9]+"
DEFINE NAMESPACE TAXONOMY       AS PATTERN "^\d+$"
DEFINE NAMESPACE UNIPROT        AS PATTERN "^([A-N,R-Z][0-9]([A-Z][A-Z, 0-9][A-Z, 0-9][0-9]){1,2})|([O,P,Q][0-9][A-Z, 0-9][A-Z, 0-9][A-Z, 0-9][0-9])(\.\d+)?$"
DEFINE NAMESPACE PUBCHEM        AS PATTERN "^\d+$"

###############
# Annotations #
###############

# Annotations defined with regular expressions
# --------------------------------------------
DEFINE ANNOTATION Species       AS PATTERN "^\d+$"

# Annotations hosted on https://arty.scai.fraunhofer.de/artifactory/bel/annotation
# --------------------------------------------------------------------------------
DEFINE ANNOTATION Anatomy       AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/anatomy/anatomy-20170511.belanno"
DEFINE ANNOTATION CellLine      AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-line/cell-line-20170511.belanno"
DEFINE ANNOTATION CellStructure AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-structure/cell-structure-20170511.belanno"
DEFINE ANNOTATION Cell          AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell/cell-20170511.belanno"
DEFINE ANNOTATION Confidence    AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/confidence/confidence-1.0.0.belanno"
DEFINE ANNOTATION Disease       AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/disease/disease-20170511.belanno"
DEFINE ANNOTATION Gender        AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/gender/gender-1.0.0.belanno"
DEFINE ANNOTATION MeSHAnatomy   AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-anatomy/mesh-anatomy-20170511.belanno"
DEFINE ANNOTATION MeSHDisease   AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-diseases/mesh-diseases-20170511.belanno"
DEFINE ANNOTATION Subgraph      AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/neurommsig/neurommsig-1.0.3.belanno"
DEFINE ANNOTATION TextLocation  AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/text-location/text-location-1.0.1.belanno"

##############
# Statements #
##############

SET STATEMENT_GROUP = "Sandra"

# Add statements below this comment

SET Citation = {"PubMed","21882945"}

SET Evidence = "Tauopathies are a family of neurodegenerative
disorders characterized by the appearance of
aggregates of the microtubule-associating protein, tau."
a(HBP:"Tau aggregates") -> path(MESH:Tauopathies)

SET Evidence = "For example, tau pathology closely correlates to neuron loss and
cognitive deficits"
path(MESH:Tauopathies) pos bp(GO:"neuron death")
path(MESH:Tauopathies) neg bp(GO:cognition)

SET Evidence = "Phosphorylation of tau by the kinases GSK3b,
Cdk5 and MARK2 is a major regulator of its microtubule interactions"
act(p(HGNC:GSK3B))  => p(HGNC:MAPT,pmod(Ph))
act(p(HGNC:CDK5)) => p(HGNC:MAPT,pmod(Ph))
act(p(HGNC:MARK2)) => p(HGNC:MAPT,pmod(Ph))
p(HGNC:MAPT,pmod(Ph)) reg complex(p(HGNC:MAPT),a(GO:microtubule))

SET Evidence = "Importantly, MARK2-based phosphorylation of tau is accelerated
by the priming activity of either Cdk5 or GSK3b [29], suggesting that tau phosphorylation
involves a series of ordered kinase events."
act(p(HGNC:MARK2)) => p(HGNC:MAPT,pmod(Ph))
p(HGNC:GSK3B) -> act(p(HGNC:MARK2))
p(HGNC:CDK5) -> act(p(HGNC:MARK2))

SET Evidence = "In general, phosphorylation of tau reduces its
affinity for microtubules [30], while dephosphorylation
via enzymes such as PP2A and PP5 restores binding"
p(HGNC:MAPT,pmod(Ph)) -| complex(p(HGNC:MAPT),a(GO:microtubule))
p(HGNC:MAPT) -> complex(p(HGNC:MAPT),a(GO:microtubule))
p(HGNC:PPP5C) -| p(HGNC:MAPT,pmod(Ph))
p(HGNC:PPP2R5B) -| p(HGNC:MAPT,pmod(Ph))

SET Evidence = "However, hyperphosphorylated forms of tau are
more prone to aggregate, which might decrease
their solubility and remove them from normal cycling"
p(HGNC:MAPT,pmod(HBP:hyperphosphorylation)) -> a(HBP:"Tau aggregates")

SET Evidence = "There are no cures for any tauopathy.
Neuroprotective agents, such as acetylcholinesterase
inhibitors and NMDA antagonists, have been approved for use in the clinic, based
on their ability to slow the rate of cognitive
decline in patients with moderate to severe AD (reviewed in [36])"
SET MeSHDisease = "Alzheimer Disease"
a(PUBCHEM:134222899) pos bp(GO:cognition)
a(CHEBI:"NMDA receptor antagonist") pos bp(GO:cognition)
UNSET MeSHDisease

SET Evidence = "These efforts have produced early-stage molecules of
multiple different chemical classes, including
rhodanine-based inhibitors, phenylthiazolylhydrazides,
N-phenylamines, anthraquinones, benzothiazoles, phenothiazines and polyphenols [41]"
# compounds that directly block the aggregation of tau
a(CHEBI:rhodanine) -| a(HBP:"Tau aggregates")
a(HBP:"Phenylthiazolyl-hydrazide") -| a(HBP:"Tau aggregates")
a(PUBCHEM:53789478) -| a(HBP:"Tau aggregates")
a(CHEBI:anthraquinone) -| a(HBP:"Tau aggregates")
a(CHEBI:benzothiazoles) -| a(HBP:"Tau aggregates")
a(CHEBI:phenothiazines) -| a(HBP:"Tau aggregates")
a(CHEBI:polyphenol) -| a(HBP:"Tau aggregates")

SET Evidence = "All proteins, including tau,
are subject to extensive regulation by the cellular
quality control pathways, which carefully control
the balance between protein expression and
turnover to maintain healthy protein homeostasis (or proteostasis)"
bp(HBP:Proteostasis) reg p(HGNC:MAPT)
bp(HBP:Proteostasis) reg a(MESH:Proteins)

SET Evidence = "Interestingly, tau clearance
is known to be impaired in the aging brain [45],
supporting the idea that diminished quality control
might be conducive to certain tauopathies,
such as AD, which are linked to aging"
bp(GO:aging) neg deg(p(HGNC:MAPT))

SET Evidence = "Furthermore, recent evidence suggests that tau
is essential for the neurotoxicity of amyloid-b, providing a possible link between these classic
AD targets and suggesting that reductions in tau levels might be important via multiple,
beneficial mechanisms [46â48]"
a(CHEBI:"amyloid-beta") -> path(HBP:neurotoxicity)
p(HGNC:MAPT) -> path(HBP:neurotoxicity)

SET Evidence = "Molecular chaperones are abundant and highly
conserved proteins that assume an important role in protein quality control"
a(MESH:"Molecular Chaperones") -- bp(GO:"protein quality control for misfolded or incompletely synthesized proteins")

SET Evidence = "Several members of the chaperone family are upregulated in
response to stress and, thus, these factors have been termed heat shock proteins (Hsps)"
bp(GO:"cellular response to stress") -> a(MESH:"Heat-Shock Proteins")

SET Evidence = "The expression of Hsps is regulated by heat shock
factor 1 (HSF1), which, under stress conditions,
becomes associated with heat shock elements
to elevate the transcription of Hsps and other proteins [51]."
p(HGNC:HSF1) -> a(MESH:"Heat-Shock Proteins")

SET Evidence = "Importantly, the Hsps are also critical at the end of a proteinâs life,
as they facilitate turnover by the proteasome system
and the clearance of proteotoxic aggregates by autophagy [53]"
a(MESH:"Heat-Shock Proteins") -> bp(GO:"proteasomal protein catabolic process")
a(MESH:"Heat-Shock Proteins") -> bp(GO:autophagy)

SET Evidence = "The intrinsic ATPase activity of Hsp70
is very weak (~0.2 nmol/Î¼g/min) [60] and, under physiological
conditions, it is regulated by cochaperones, including
J-proteins and nucleotide exchange factors (NEFs)."
p(INTERPRO:"Chaperone J-domain superfamily") -> act(p(INTERPRO:"Heat shock protein 70 family"))
a(MESH:"Guanine Nucleotide Exchange Factors") -> act(p(INTERPRO:"Heat shock protein 70 family"))

SET Evidence = "Briefly, J-proteins cause
a conformational change in Hsp70s that accelerates
ATP hydrolysis [61], while NEFs facilitate ADP release [62]"
p(INTERPRO:"Chaperone J-domain superfamily") -> rxn(reactants(a(CHEBI:ATP)),products(a(CHEBI:ADP),a(CHEBI:"phosphate(3-)")))
a(MESH:"Guanine Nucleotide Exchange Factors") -> a(CHEBI:ADP)

SET Evidence = "For example, VER-155008 is an ATP-competitive compound developed by
structure-guided design [69,70]"
a(PUBCHEM:25195348) -| act(a(MESH:"Adenosine Triphosphatases"))

SET Evidence = "As might be expected given the diverse mechanisms of these compounds, known
Hsp70 inhibitors represent a variety of chemical classes, including dihydropyrimidines, adenosine
analogs, polyamines and others (Figure 1) [52,63]. Moreover, many of these inhibitors, including
methylene blue and MKT-077, have poorly understood mechanisms"
a(PUBCHEM:1056) -| act(p(INTERPRO:"Heat shock protein 70 family"))
a(CHEBI:adenosine) -| act(p(INTERPRO:"Heat shock protein 70 family"))
a(CHEBI:polyamine) -| act(p(INTERPRO:"Heat shock protein 70 family"))
a(CHEBI:"methylene blue") -| act(p(INTERPRO:"Heat shock protein 70 family"))
a(PUBCHEM:6444403) -| act(p(INTERPRO:"Heat shock protein 70 family"))

SET Evidence = "Recent structural studies have suggested that Hsp90 functions as a homodimer in which
the C-terminal domains of two Hsp90 molecules are in contact at the bottom of the âV-shapedâ open conformer"
complex(p(FPLX:HSP90),p(FPLX:HSP90)) -> act(p(FPLX:HSP90))

SET Evidence = "As in the case of Hsp70, cochaperones of Hsp90, such as Aha1, cdc37 and
TPR domain-containing proteins, regulate its ATPase activity and control its conformational
transitions (reviewed in [84])."
p(HGNC:AHSA1) reg act(p(FPLX:HSP90))
p(HGNC:CDC37) reg act(p(FPLX:HSP90))
p(INTERPRO:"Tetratricopeptide repeat-containing domain") reg act(p(FPLX:HSP90))

SET Evidence = "Work on Hsp90 inhibitors benefited from the early discovery of the natural product, geldanamycin,
which competes with ATP and induces destabilization of Hsp90-bound proteins [87]"
a(CHEBI:"geldanamycin") -| act(p(FPLX:HSP90))

SET Evidence = "Since this discovery, a number of high-affinity analogs, such as 17-AAG, and alternative synthetic
scaffolds, including radicicol and PU-H71, have been reported (Figure 1) [85,88]. These compounds
bind in either the N-terminal ATP-binding site (e.g., 17-AAG, radicicol and PU-H71) [89] or
C-terminal dimerization domain (e.g., novobiocin and A4) [90,91], and they show great promise
as both anticancer compounds and research tools for understanding Hsp90 biology"
a(CHEBI:radicicol) => complex(a(CHEBI:radicicol),p(INTERPRO:"Heat shock protein Hsp90, N-terminal"))
a(CHEBI:radicicol) =| act(p(FPLX:HSP90))
a(PUBCHEM:9549213) => complex(a(PUBCHEM:9549213),p(INTERPRO:"Heat shock protein Hsp90, N-terminal"))
a(PUBCHEM:9549213) =| act(p(FPLX:HSP90))
a(CHEBI:tanespimycin) => complex(a(CHEBI:tanespimycin),p(INTERPRO:"Heat shock protein Hsp90, N-terminal"))
a(CHEBI:tanespimycin) =| act(p(FPLX:HSP90))
a(CHEBI:novobiocin) => complex(a(CHEBI:novobiocin),p(INTERPRO:"HSP90, C-terminal domain"))
a(CHEBI:novobiocin) =| act(p(FPLX:HSP90))
a(PUBCHEM:501026) => complex(a(PUBCHEM:501026),p(INTERPRO:"HSP90, C-terminal domain"))
a(PUBCHEM:501026) =| act(p(FPLX:HSP90))

SET Evidence = "More recently, there has also been interest in developing
compounds, such as celastrol (Figure 1), that selectively disrupt association of co-chaperones
with Hsp90 as an alternative way to control chaperone activity [93â96]."
a(CHEBI:celastrol) -- act(p(FPLX:HSP90))

SET Evidence = "These proteins are ATP-independent chaperones that
undergo homo-oligomerization in response to stress [97,98]"
#these proteins: Hsp27 oligomers
bp(GO:"cellular response to stress") -> a(HBP:"Hsp27 oligomers")

SET Evidence = "To allow substrate release, Hsp27 oligomerization is
reversible; a process that is regulated, at least in part, by phosphorylation"
bp(GO:phosphorylation) reg a(HBP:"Hsp27 oligomers")

SET Evidence = "During protein quality control, Hsp70, Hsp90 and Hsp27 (and their co-chaperones) often work
in concert. If prolonged misfolding is detected, the chaperones shuttle the protein to a degradation
endpoint, such as the proteasome or autophagy"
p(INTERPRO:"Heat shock protein 70 family") -> bp(GO:"protein quality control for misfolded or incompletely synthesized proteins")
p(INTERPRO:"Heat shock protein 70 family") -> bp(GO:"proteasomal protein catabolic process")
p(INTERPRO:"Heat shock protein 70 family") -> bp(GO:autophagy)
p(FPLX:HSP90) -> bp(GO:"protein quality control for misfolded or incompletely synthesized proteins")
p(FPLX:HSP90) -> bp(GO:"proteasomal protein catabolic process")
p(FPLX:HSP90) -> bp(GO:autophagy)
p(HGNC:HSPB1) -> bp(GO:"protein quality control for misfolded or incompletely synthesized proteins")
p(HGNC:HSPB1) -> bp(GO:"proteasomal protein catabolic process")
p(HGNC:HSPB1) -> bp(GO:autophagy)

SET Evidence = "Alternatively, either Hsp70 or Hsp90 can recruit the ubiquitin
E3 ligase, C-terminal Hsp70 interacting protein (CHIP), to degrade the bound substrate [104]"
p(INTERPRO:"Heat shock protein 70 family") -> act(p(HGNC:STUB1))
p(FPLX:HSP90) -> act(p(HGNC:STUB1))
act(p(HGNC:STUB1)) -> bp(GO:"protein catabolic process")

SET Evidence = "For example, the co-chaperones cdc37, a peptidyl-prolyl cis-trans isomerase (PPIase) family
member, and p23 are all critical for the transfer of kinases to Hsp90 and maturation of the active protein [76,105]"
p(HGNC:CDC37) -> complex(a(MESH:"Protein Kinases"),p(FPLX:HSP90))
p(HGNC:PTGES3) -> complex(a(MESH:"Protein Kinases"),p(FPLX:HSP90))

SET Evidence = "In addition, Hsp90âs hydrolysis of ATP, which is stimulated by Aha1, facilitates
polypeptide release [82,106] and transfer to CHIP or other E3 ligases [107,108]"
p(HGNC:AHSA1) -> rxn(reactants(a(CHEBI:ATP)),products(a(CHEBI:ADP),a(CHEBI:"phosphate(3-)")))
p(HGNC:AHSA1) -> complex(a(CHEBI:polypeptide),p(HGNC:STUB1))

SET Evidence = "Although both Hsp70 and Hsp90 can promote degradation of client proteins, it has
recently been shown that, functionally, the Hsp70 complex often dominates triage decisions [85,107,109]"
p(INTERPRO:"Heat shock protein 70 family") -> bp(GO:"protein catabolic process")
p(FPLX:HSP90) -> bp(GO:"protein catabolic process")

SET Evidence = "However, under potentially proteotoxic conditions, the
post-translational modifications or mutations that damage tauâs affinity for microtubules and
favor its aggregation are thought to generate a molecular âdanger signalâ that specifically alerts
the quality control system [112,113]."
p(HGNC:MAPT,var("?")) -> a(HBP:"Tau aggregates")
p(HGNC:MAPT,var("?")) -| complex(p(HGNC:MAPT),a(GO:microtubule))

SET Evidence = "Hsp70 has been shown to both stabilize binding
of tau to microtubules [114] and promote its degradation in combination with CHIP [115,116]"
p(INTERPRO:"Heat shock protein 70 family") -> complex(p(HGNC:MAPT),a(GO:microtubule))
complex(p(HGNC:STUB1),p(INTERPRO:"Heat shock protein 70 family")) -> deg(p(HGNC:MAPT))

SET Evidence = "In addition, recent work has demonstrated that Hsc70, the constitutive cytosolic form of
Hsp70s, also dynamically regulates the association of tau with microtubules"
p(HGNC:HSPA8) reg complex(p(HGNC:MAPT),a(GO:microtubule))

SET Evidence = "In fact, recent work from our group has shown that inhibition of the ATPase
activity of Hsp70/Hsc70 promotes proteasomal degradation of tau; whereas activation results
in tau accumulation [117]"
act(p(INTERPRO:"Heat shock protein 70 family")) -> deg(p(HGNC:MAPT))
act(p(HGNC:HSPA8)) -> deg(p(HGNC:MAPT))

SET Evidence = "Hsp90 was also shown to increase association of tau with microtubules [114]; however, its binding
is not well characterized and it is not known whether this is a direct or indirect process"
p(FPLX:HSP90) -> complex(p(HGNC:MAPT),a(GO:microtubule))

SET Evidence = "For example, it has recently been shown that Hsp90
promotes tauâs phosphorylation by its ability to stabilize GSK3b [118]"
p(FPLX:HSP90) -> p(HGNC:MAPT,pmod(Ph))
p(FPLX:HSP90) reg act(p(HGNC:GSK3B))

SET Evidence = "However, this issue is more complicated, as other work has shown that chemical
inhibition of Hsp90 by 17-AAG and other inhibitors reduces cellular levels of two phospho-
tau species, pS202/T205 and pS396/S404, both of which are relevant to AD pathogenesis [119]."
a(CHEBI:tanespimycin) -| act(p(FPLX:HSP90))
a(CHEBI:tanespimycin) -| p(HGNC:MAPT,pmod(Ph,Ser,202),pmod(Ph,Thr,205))
a(CHEBI:tanespimycin) -| p(HGNC:MAPT,pmod(Ph,Ser,396),pmod(Ph,Ser,404))
p(HGNC:MAPT,pmod(Ph,Ser,202),pmod(Ph,Thr,205)) pos path(MESH:"Alzheimer Disease")
p(HGNC:MAPT,pmod(Ph,Ser,396),pmod(Ph,Ser,404)) pos path(MESH:"Alzheimer Disease")

SET Evidence = "Interestingly, it was recently found that reducing the levels of Akt, another client of
the Hsp90/CHIP complex, facilitates tau degradation [123], suggesting a synchronized balance
between competing Hsp90 substrates that may be driven, in part, by their relative abundance
or susceptibility to Hsp90 binding"
p(HGNC:AKT1) -- complex(p(HGNC:STUB1),p(FPLX:HSP90))
p(HGNC:AKT1) neg deg(p(HGNC:MAPT))

SET Evidence = "Together, multiple studies suggest that Hsp90
regulates the stability of both phospho- and mutant-tau"
p(FPLX:HSP90) reg p(HGNC:MAPT,pmod(Ph))
p(FPLX:HSP90) reg p(HGNC:MAPT,var("?"))

SET Evidence = "Hsp27 has emerged as a potential target for tau regulation based on early findings that it
preferentially binds to phosphorylated and hyperphosphorylated tau and promotes their clearance [125,126]"
p(HGNC:HSPB1) => complex(p(HGNC:MAPT,pmod(HBP:hyperphosphorylation)),p(HGNC:HSPB1))
p(HGNC:HSPB1) => complex(p(HGNC:MAPT,pmod(Ph)),p(HGNC:HSPB1))
complex(p(HGNC:MAPT,pmod(Ph)),p(HGNC:HSPB1)) -> deg(p(HGNC:MAPT,pmod(Ph)))
complex(p(HGNC:MAPT,pmod(HBP:hyperphosphorylation)),p(HGNC:HSPB1)) -> deg(p(HGNC:MAPT,pmod(HBP:hyperphosphorylation)))

SET Evidence = "However, astrocyte-derived Hsp27 has been shown to promote tau accumulation
and Hsp27 associates with tau tangles in a mouse model [127,128], suggesting a more complex relationship"
SET Cell = "astrocyte"
p(HGNC:HSPB1) -> p(HGNC:MAPT)
UNSET Cell
SET Species = "10090"
p(HGNC:HSPB1) => complex(p(HGNC:HSPB1),a(MESH:"Neurofibrillary Tangles"))
UNSET Species

SET Evidence = "Recently, our group demonstrated that viral delivery of wild-type Hsp27
into the brains of tau-transgenic mice reduced tau levels and rescued long-term potentiation deficits."
SET Species = "10090"
p(HGNC:HSPB1) -| p(HGNC:MAPT)
p(HGNC:HSPB1) pos bp(GO:"long-term synaptic potentiation")
UNSET Species

SET Evidence = "BAG1 is upregulated in the hippocampus of AD patients [130], where it
associates with tau and increases tau levels in cooperation with Hsp70 [131]"
SET MeSHAnatomy = "Hippocampus"
p(HGNC:BAG1) pos path(MESH:"Alzheimer Disease")
p(HGNC:BAG1) => complex(p(HGNC:BAG1),p(HGNC:MAPT))
complex(p(HGNC:BAG1),p(INTERPRO:"Heat shock protein 70 family")) -> p(HGNC:MAPT)
UNSET MeSHAnatomy

SET Evidence = "BAG1 silencing decreases tau levels, consistent with a critical
role for this co-chaperone in protecting tau from degradation."
p(HGNC:BAG1) -| deg(p(HGNC:MAPT))

SET Evidence = "However, another related BAG family member, BAG2, interacts with Hsp70
and tau but, unlike BAG1, assists clearance of phosphorylated tau [132]"
p(HGNC:BAG2) => complex(p(HGNC:BAG2),p(HGNC:MAPT),p(INTERPRO:"Heat shock protein 70 family"))
p(HGNC:BAG2) -- deg(p(HGNC:MAPT,pmod(Ph)))

SET Evidence = "This co-chaperone is of interest in tauopathies because Hsp110
knockout mice show an age-dependent accumulation of phosphorylated tau in the hippocampus [135]."
#this co-chaperone: Hsp110
SET MeSHAnatomy = "Hippocampus"
SET Species = "10090"
p(HGNC:HSPH1) -| p(HGNC:MAPT,pmod(Ph))
UNSET Species
UNSET MeSHAnatomy

SET Evidence = "Recently, the co-chaperone FK506-binding protein 51 kDa (FKBP51) has been implicated
as a modulator of tau binding to microtubules"
p(HGNC:FKBP5) reg complex(p(HGNC:MAPT),a(GO:microtubule))

SET Evidence = "In relation to tau biology, FKBP51 enhances the association of Hsp90 with tau,
co-localizes with tau in murine neurons, coimmunoprecipitates
with tau in AD tissue samples and increases with age in an AD mouse model [136]."
p(HGNC:FKBP5) -> complex(p(HGNC:MAPT),p(FPLX:HSP90))
SET MeSHDisease = "Alzheimer Disease"
p(HGNC:FKBP5) => complex(p(HGNC:MAPT),p(HGNC:FKBP5))
bp(GO:aging) pos p(HGNC:FKBP5)
UNSET MeSHDisease

SET Evidence = "These interactions may be functionally important because silencing FKBP51
reduces tau and phosphorylated-tau levels [136]."
p(HGNC:FKBP5) -> p(HGNC:MAPT)
p(HGNC:FKBP5) -> p(HGNC:MAPT,pmod(Ph))

SET Evidence = "Finally, the FKBP51âHsp90 complex has been proposed to be responsible for the interaction of
tau with phosphatases, helping to restore binding to microtubules [137]."
complex(p(HGNC:FKBP5),p(FPLX:HSP90)) -> complex(p(HGNC:MAPT),a(MESH:"Protein Phosphatase 2"))
complex(p(HGNC:MAPT),a(MESH:"Protein Phosphatase 2")) -> complex(p(HGNC:MAPT),a(GO:microtubule))

SET Evidence = "In this model,accumulation of an Hsp70âsubstrate complex
(either via treatment with chemical inhibitors or because of intrinsic properties of the substrate)
might allow enough time for a degradation factor (e.g., CHIP) to bind and facilitate polyubiquitination."
complex(p(INTERPRO:"Heat shock protein 70 family"),a(MESH:Proteins)) pos complex(p(HGNC:STUB1),p(INTERPRO:"Heat shock protein 70 family"),a(MESH:Proteins))
complex(p(HGNC:STUB1),p(INTERPRO:"Heat shock protein 70 family"),a(MESH:Proteins)) -> bp(GO:"protein polyubiquitination")

SET Evidence = "For example, Hsp90 inhibitors cause degradation of tau and many
cancer-related substrates [85]."
a(CHEBI:"Hsp90 inhibitor") -> deg(p(HGNC:MAPT))

SET Evidence = "Moreover, these compounds were found to prolong binding of
Hsp90 to a model substrate, which was sufficient to promote its degradation [142]"
#these inhibitors: Hsp90 inhibitors
a(CHEBI:"Hsp90 inhibitor") -> complex(a(MESH:Proteins),p(FPLX:HSP90))
complex(a(MESH:Proteins),p(FPLX:HSP90)) -> deg(a(MESH:Proteins))

SET Evidence = "The fact that Hsp70 inhibitors reduce tau levels without affecting other likely
Hsp70 substrates, such as a-synuclein or TDP-43, generally supports the idea that substrates
are actively involved in dictating their own fate [117]"
act(p(INTERPRO:"Heat shock protein 70 family")) -> p(HGNC:MAPT)

SET Evidence = "This model is consistent with the data that hyperphosphorylated
tau appears to be specifically selected for degradation by some chaperone
machines, such as the Hsp90âFKBP51 complex, without effects on normal tau [132,136]."
complex(p(HGNC:FKBP5),p(FPLX:HSP90)) -> deg(p(HGNC:MAPT,pmod(HBP:hyperphosphorylation)))

SET Evidence = "For example, the Hsp90 inhibitor geldanamycin
mimics ADP binding, but also inhibits recruitment
of p23, which is a necessary step in client maturation [145]."
a(CHEBI:"geldanamycin") -| act(p(FPLX:HSP90))
a(CHEBI:"geldanamycin") -| complex(p(FPLX:HSP90),p(HGNC:PTGES3))

SET Evidence = "For example, BAG-2 inhibits client ubiquitination by CHIP by interfering with the
interaction between CHIP and E2 ubiquitin-conjugating enzymes [148]."
p(HGNC:BAG2) -| act(p(HGNC:STUB1))
p(HGNC:BAG2) -| bp(GO:"protein ubiquitination")
act(p(HGNC:STUB1)) -> bp(GO:"protein ubiquitination")
p(HGNC:BAG2) -| complex(p(HGNC:STUB1),p(HGNC:UBA2))

SET Evidence = "In another example, McClellan et al. showed that von HippelâLindau
tumor-suppressor protein requires Hsp70 for its folding and degradation, whereas Hsp90 is only
required for degradation [149]."
complex(p(HGNC:VHL),p(INTERPRO:"Heat shock protein 70 family")) -> deg(p(HGNC:VHL))
complex(p(HGNC:VHL),p(FPLX:HSP90)) -> deg(p(HGNC:VHL))

SET Evidence = "HOP was also required for degradation, indicating that transfer
of von HippelâLindau from the Hsp70 complex
to Hsp90 is a necessary part of its degradation pathway."
#degradation of VHL
complex(p(HGNC:STIP1),p(HGNC:VHL)) -> deg(p(HGNC:VHL))

SET Evidence = "For example, we found that dihydropyrimidine-based
molecules can either force the association of a prokaryotic Hsp70 with its J-protein partner
or, with a relatively modest change in chemical structure, related compounds could block this contact [73]."
a(PUBCHEM:1056) reg complex(p(INTERPRO:"Chaperone J-domain superfamily"),p(INTERPRO:"Heat shock protein 70 family"))

SET Evidence = "Using high-throughput screening against the J-protein-stimulated ATPase activity
of an Hsp70, we also found polyphenols that selectively block J-stimulated activities by interfering
with J-protein recruitment to the Hsp70 complex [72]."
a(CHEBI:polyphenol) -| complex(p(INTERPRO:"Chaperone J-domain superfamily"),p(INTERPRO:"Heat shock protein 70 family"))

SET Evidence = "However, the mechanisms that link HSF1 induction to
improved proteostasis are not yet clear"
p(HGNC:HSF1) -> bp(HBP:Proteostasis)

##########################################################


UNSET STATEMENT_GROUP
